US Edition
Appili’s ATI-1701 Vaccine Shows Full Protection Against Aerosolized Tularemia in Preclinical Study
Summary by Global Biodefense
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.1 Articles
1 Articles
Appili’s ATI-1701 Vaccine Shows Full Protection Against Aerosolized Tularemia in Preclinical Study
Appili Therapeutics Inc. has announced new peer-reviewed findings supporting the efficacy of its tularemia vaccine candidate, ATI-1701, in protecting against aerosolized Francisella tularensis exposure in multiple animal models. The study, [...] Read the rest of Appili Therapeutics Reports Strong Preclinical Protection from ATI-1701 Tularemia Vaccine at Global Biodefense
Coverage Details
Total News Sources1
Leaning Left0Leaning Right0Center0Last UpdatedBias DistributionNo sources with tracked biases.
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
